NO326926B1 - Anvendelse av eikosapentaensyre og/eller stearidonsyre i fremstilling av medikamenter - Google Patents
Anvendelse av eikosapentaensyre og/eller stearidonsyre i fremstilling av medikamenter Download PDFInfo
- Publication number
- NO326926B1 NO326926B1 NO19991635A NO991635A NO326926B1 NO 326926 B1 NO326926 B1 NO 326926B1 NO 19991635 A NO19991635 A NO 19991635A NO 991635 A NO991635 A NO 991635A NO 326926 B1 NO326926 B1 NO 326926B1
- Authority
- NO
- Norway
- Prior art keywords
- epa
- present
- acid
- fatty acids
- weight
- Prior art date
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 65
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 63
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 63
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 63
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 title claims abstract description 27
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 13
- 229930195729 fatty acid Natural products 0.000 claims abstract description 13
- 239000000194 fatty acid Substances 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 11
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims abstract description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 30
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 229940090949 docosahexaenoic acid Drugs 0.000 description 13
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102100026918 Phospholipase A2 Human genes 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 5
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- 101710096328 Phospholipase A2 Proteins 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- 108010058864 Phospholipases A2 Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- -1 LA z Chemical compound 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000024453 abnormal involuntary movement Diseases 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-M all-cis-5,8,11,14,17-icosapentaenoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O JAZBEHYOTPTENJ-JLNKQSITSA-M 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- KFEVDPWXEVUUMW-UHFFFAOYSA-N docosanoic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 KFEVDPWXEVUUMW-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621294.9A GB9621294D0 (en) | 1996-10-11 | 1996-10-11 | Fatty acid treatment |
| GBGB9626062.5A GB9626062D0 (en) | 1996-10-11 | 1996-12-16 | Fatty acid treatment |
| PCT/GB1997/002738 WO1998016216A1 (en) | 1996-10-11 | 1997-10-07 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO991635D0 NO991635D0 (no) | 1999-04-06 |
| NO991635L NO991635L (no) | 1999-06-07 |
| NO326926B1 true NO326926B1 (no) | 2009-03-16 |
Family
ID=26310221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19991635A NO326926B1 (no) | 1996-10-11 | 1999-04-06 | Anvendelse av eikosapentaensyre og/eller stearidonsyre i fremstilling av medikamenter |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US6331568B1 (cs) |
| EP (1) | EP0956013B1 (cs) |
| JP (1) | JP4151853B2 (cs) |
| KR (2) | KR20060061409A (cs) |
| CN (1) | CN1109543C (cs) |
| AT (1) | ATE236627T1 (cs) |
| AU (1) | AU731692C (cs) |
| BR (1) | BR9713479A (cs) |
| CA (1) | CA2268257C (cs) |
| CZ (1) | CZ293704B6 (cs) |
| DE (1) | DE69720787T2 (cs) |
| DK (1) | DK0956013T3 (cs) |
| ES (1) | ES2195175T3 (cs) |
| ID (1) | ID21473A (cs) |
| IL (1) | IL129367A0 (cs) |
| IS (1) | IS2180B (cs) |
| NO (1) | NO326926B1 (cs) |
| NZ (1) | NZ334852A (cs) |
| PL (1) | PL190181B1 (cs) |
| PT (1) | PT956013E (cs) |
| SK (1) | SK285210B6 (cs) |
| TR (1) | TR199900786T2 (cs) |
| TW (1) | TW429145B (cs) |
| WO (1) | WO1998016216A1 (cs) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ293704B6 (cs) * | 1996-10-11 | 2004-07-14 | Scarista Limited | Farmaceutický přípravek pro léčení schizofrenie a/nebo pozdní dyskineze, obsahující kyselinu ikosapentaenovou a/nebo kyselinu stearidonovou a způsob výroby léčiva pro léčení schizofrenie a/nebo pozdní dyskineze |
| NZ505761A (en) * | 1998-01-28 | 2003-08-29 | Warner Lambert Co | Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis |
| US6107334A (en) | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| US7138431B1 (en) | 1998-02-23 | 2006-11-21 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| FR2788437B1 (fr) * | 1999-01-14 | 2006-08-11 | Inst Rech Biolog Sa | Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB9901808D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Drugs for treatment of psychiatric and brain disorders |
| AU2006201772B2 (en) * | 1999-01-27 | 2010-02-04 | Amarin Neuroscience Limited | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| GB9904895D0 (en) * | 1999-03-03 | 1999-04-28 | Scarista Limited | Regulators of coenzyme-A-independent transacylase as psychotropic drugs |
| WO2001068104A1 (en) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
| IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
| IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
| AU2002309931A1 (en) * | 2001-05-17 | 2002-11-25 | Pilot Therapeutics, Inc. | Method for enriching tissues in long chain polyunsaturated fatty acids |
| EP1576970B1 (en) | 2001-11-08 | 2010-03-24 | Ziscoat N.V. | Intraluminal device with a coating containing a therapeutic agent |
| NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| NZ539106A (en) | 2002-10-10 | 2007-02-23 | Yeda Res & Dev | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
| GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| CH698539A8 (de) | 2003-08-18 | 2009-10-15 | Btg Int Ltd | Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. |
| WO2005034874A2 (en) * | 2003-10-08 | 2005-04-21 | The Mclean Hospital Corporation | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
| CA2542023A1 (en) * | 2003-10-08 | 2005-09-22 | The Mclean Hospital Corporation | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
| AU2005208832A1 (en) * | 2004-01-19 | 2005-08-11 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
| ITMI20040069A1 (it) * | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
| US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
| US20050266051A1 (en) * | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
| WO2005122767A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| WO2005123097A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder |
| WO2006020703A1 (en) * | 2004-08-11 | 2006-02-23 | The Mclean Hospital Corporation | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| EP1804717A4 (en) * | 2004-09-28 | 2015-11-18 | Atrium Medical Corp | DRUG DELIVERY COATING FOR USE WITH ONE STENT |
| US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
| US20090011116A1 (en) * | 2004-09-28 | 2009-01-08 | Atrium Medical Corporation | Reducing template with coating receptacle containing a medical device to be coated |
| EP1811935B1 (en) | 2004-09-28 | 2016-03-30 | Atrium Medical Corporation | Heat cured gel and method of making |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US20060083768A1 (en) * | 2004-09-28 | 2006-04-20 | Atrium Medical Corporation | Method of thickening a coating using a drug |
| US7550286B2 (en) | 2004-11-04 | 2009-06-23 | E. I. Du Pont De Nemours And Company | Docosahexaenoic acid producing strains of Yarrowia lipolytica |
| EP1824809A4 (en) * | 2004-11-19 | 2010-03-03 | Martek Biosciences Corp | OXYLIPINES OF LONG-CHAIN, MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US7893106B2 (en) * | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| US20090318394A1 (en) * | 2004-11-19 | 2009-12-24 | Julie Nauroth | Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same |
| GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
| GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
| GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
| GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| JP2009502745A (ja) * | 2005-07-08 | 2009-01-29 | マーテック バイオサイエンシーズ コーポレーション | 認知症および前認知症に関連した状態を治療するための多価不飽和脂肪酸 |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| AU2006304590A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
| JP2009520824A (ja) * | 2005-12-20 | 2009-05-28 | セネストラ エルエルシー | オメガ３脂肪酸製剤 |
| WO2007090162A2 (en) * | 2006-01-31 | 2007-08-09 | Martek Biosciences Corporation | OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| EP2626091B1 (en) | 2006-11-06 | 2016-09-28 | Atrium Medical Corporation | Coated surgical mesh |
| US20100130611A1 (en) * | 2006-12-20 | 2010-05-27 | Cenestra Llc | Omega 3 fatty acid formulations |
| EP2120920A4 (en) * | 2007-02-20 | 2011-06-15 | Martek Biosciences Corp | OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE |
| EP2117301A4 (en) * | 2007-02-26 | 2010-04-14 | Yeda Res & Dev | USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS |
| EP2114155A4 (en) * | 2007-02-26 | 2014-04-16 | Yeda Res & Dev | AMINO-PHENYL-ACETIC ACID OCTADEC-9- (Z) ENANTIOMERS, THEIR SALTS AND USES THEREOF |
| US20090117253A1 (en) * | 2007-10-03 | 2009-05-07 | E. I. Du Pont De Nemours And Company | Peroxisome biogenesis factor protein (pex) disruptions for altering polyunsaturated fatty acids and total lipid content in oleaginous eukaryotic organisms |
| EP2211881A4 (en) * | 2007-11-01 | 2012-01-04 | Wake Forest University School Of Medicine | COMPOSITIONS AND METHOD FOR THE PREVENTION AND TREATMENT OF SEDUCTIVES OF MAMMALS |
| US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| WO2009086281A1 (en) * | 2007-12-21 | 2009-07-09 | Martek Biosciences Corporation | Method for preparation of oxylipins |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| AU2009288066B2 (en) | 2008-09-02 | 2015-12-24 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| CA2773031C (en) | 2008-09-09 | 2021-03-02 | Orygen Youth Health Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
| AU2015203289B2 (en) * | 2008-09-09 | 2017-03-16 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
| US8060617B2 (en) * | 2008-12-19 | 2011-11-15 | Cisco Technology, Inc. | Reserving network resources during scheduling of meeting event |
| SI2395991T1 (sl) | 2009-02-10 | 2013-12-31 | Amarin Pharmaceuticals Ireland Limited | Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
| GB0904300D0 (en) | 2009-03-12 | 2009-04-22 | Amarin Neuroscience Ltd | Essential fatty acid compounds |
| CN104042617A (zh) | 2009-04-29 | 2014-09-17 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| NZ595852A (en) | 2009-04-29 | 2014-07-25 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
| KR20120016677A (ko) | 2009-06-15 | 2012-02-24 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| NZ599061A (en) | 2009-09-23 | 2014-05-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US8372465B2 (en) * | 2010-02-17 | 2013-02-12 | Bunge Oils, Inc. | Oil compositions of stearidonic acid |
| BR112012022336A2 (pt) * | 2010-03-04 | 2020-07-21 | Amarin Pharma, Inc. | composições e seus usos para tratar e/ou prevenir doença cardiovascular |
| EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| US20140127289A1 (en) | 2010-11-29 | 2014-05-08 | Armarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| WO2012083034A1 (en) * | 2010-12-15 | 2012-06-21 | Louis Sanfilippo | Modulation of neurotrophic factors by omega-3 fatty acid formulations |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| EP2540292A1 (en) * | 2011-06-28 | 2013-01-02 | Nestec S.A. | DHA and EPA in the reduction of oxidative stress |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| EP2866801A4 (en) | 2012-06-29 | 2016-02-10 | Amarin Pharmaceuticals Ie Ltd | METHOD FOR REDUCING THE RISK OF CARDIAC CIRCULAR EVENTS IN A PATIENT IN STATIN THERAPY |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10058552B2 (en) * | 2014-02-07 | 2018-08-28 | University Of Utah Research Foundation | Combination of creatine, an omega-3 fatty acid, and citicoline |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| JP6723509B2 (ja) * | 2014-10-24 | 2020-07-15 | 日油株式会社 | 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体 |
| ES2607715B1 (es) * | 2015-10-01 | 2018-01-17 | Solutex Na, Lcc | Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| EP3750536A1 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
| GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
| GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
| CH678181A5 (cs) * | 1989-05-22 | 1991-08-15 | Nestle Sa | |
| GB9001121D0 (en) * | 1990-01-18 | 1990-03-21 | Efamol Holdings | Efa compositions and therapy |
| DE69004081T2 (de) * | 1990-05-23 | 1994-02-10 | Nestle Sa | Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen. |
| JP3400466B2 (ja) | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
| GB9224809D0 (en) | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
| GB9519661D0 (en) * | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
| CZ293704B6 (cs) * | 1996-10-11 | 2004-07-14 | Scarista Limited | Farmaceutický přípravek pro léčení schizofrenie a/nebo pozdní dyskineze, obsahující kyselinu ikosapentaenovou a/nebo kyselinu stearidonovou a způsob výroby léčiva pro léčení schizofrenie a/nebo pozdní dyskineze |
| US6590846B2 (en) * | 1999-05-21 | 2003-07-08 | Matsushita Electric Industrial Co., Ltd. | Recordable optical disk |
-
1997
- 1997-10-07 CZ CZ19991154A patent/CZ293704B6/cs not_active IP Right Cessation
- 1997-10-07 ID IDW990162A patent/ID21473A/id unknown
- 1997-10-07 IL IL12936797A patent/IL129367A0/xx active IP Right Grant
- 1997-10-07 ES ES97944022T patent/ES2195175T3/es not_active Expired - Lifetime
- 1997-10-07 NZ NZ334852A patent/NZ334852A/en not_active IP Right Cessation
- 1997-10-07 JP JP51808698A patent/JP4151853B2/ja not_active Expired - Fee Related
- 1997-10-07 US US09/284,231 patent/US6331568B1/en not_active Expired - Lifetime
- 1997-10-07 TR TR1999/00786T patent/TR199900786T2/xx unknown
- 1997-10-07 DK DK97944022T patent/DK0956013T3/da active
- 1997-10-07 CA CA002268257A patent/CA2268257C/en not_active Expired - Fee Related
- 1997-10-07 WO PCT/GB1997/002738 patent/WO1998016216A1/en not_active Ceased
- 1997-10-07 DE DE69720787T patent/DE69720787T2/de not_active Expired - Lifetime
- 1997-10-07 EP EP97944022A patent/EP0956013B1/en not_active Expired - Lifetime
- 1997-10-07 AU AU45667/97A patent/AU731692C/en not_active Ceased
- 1997-10-07 AT AT97944022T patent/ATE236627T1/de active
- 1997-10-07 BR BR9713479-1A patent/BR9713479A/pt not_active Application Discontinuation
- 1997-10-07 KR KR1020067009861A patent/KR20060061409A/ko not_active Ceased
- 1997-10-07 KR KR1019997003079A patent/KR100657642B1/ko not_active Expired - Fee Related
- 1997-10-07 PL PL97333423A patent/PL190181B1/pl not_active IP Right Cessation
- 1997-10-07 CN CN97198908A patent/CN1109543C/zh not_active Expired - Fee Related
- 1997-10-07 SK SK448-99A patent/SK285210B6/sk not_active IP Right Cessation
- 1997-10-07 PT PT97944022T patent/PT956013E/pt unknown
- 1997-10-09 TW TW086114830A patent/TW429145B/zh not_active IP Right Cessation
-
1999
- 1999-03-30 IS IS5017A patent/IS2180B/is unknown
- 1999-04-06 NO NO19991635A patent/NO326926B1/no not_active IP Right Cessation
-
2001
- 2001-09-18 US US09/956,739 patent/US6624195B2/en not_active Expired - Fee Related
- 2001-09-18 US US09/956,509 patent/US20020065319A1/en not_active Abandoned
-
2003
- 2003-05-02 US US10/428,020 patent/US20040014810A1/en not_active Abandoned
- 2003-07-11 US US10/617,184 patent/US20040048927A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO326926B1 (no) | Anvendelse av eikosapentaensyre og/eller stearidonsyre i fremstilling av medikamenter | |
| AU618814B2 (en) | Essential fatty acid compositions | |
| US5116624A (en) | Efa compositions and therapy | |
| KR20040004652A (ko) | 조효소 ｑ 및 에이코사펜타에노산（ｅｐａ） | |
| HUP0301107A2 (hu) | Zsírsavak gyógyhatású kombinációi és alkalmazásuk | |
| RU2014121891A (ru) | Улучшение узнавания | |
| CA2073913A1 (en) | Preparation of fatty acid medicaments | |
| AU2003302679B2 (en) | Use of docosahexanoic acid as active substance for the treatment of lipodystrophy | |
| HK1020316B (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid | |
| MXPA99003365A (es) | Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico | |
| IL129367A (en) | Pharmaceutical preparations comprising an oil containing eicosapentaenoic acid and/or stearidonic acid for the treatment of psychiatric disorders and a novel stearidonic acid-containing oil therefor | |
| HUP0000419A2 (hu) | Eikozapentaénsavat és/vagy sztearidonsavat tartalmazó gyógyászati készítmény | |
| NZ239126A (en) | The use of essential fatty acids to treat schizophrenia and associated tardive dyskinesia | |
| RU99106551A (ru) | Применение арахидоновой кислоты и/или докозагексаеновой кислоты для получения лекарства для лечения диспраксии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |